Ref ID: 18686
Author:
M. A. Pfaller, MD – Cons, S. A. Messer, MS – MT, R. N. Jones, MD – CEO, M. Castanheira, PhD – Dir;
Author address:
JMI Lab., N Liberty, IA.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: The SENTRY Program monitors global susceptibility (S) and R rates of newer and established antifungal agents. We report the echinocandin (EC) and triazole (TZ) antifungal S patterns for 3,416 contemporary clinical isolates of yeasts and moulds. Methods: 3,416 isolates were obtained from 98 laboratories in 34 countries during 2010-2011. Yeasts not presumptively identified (ID) by CHROMAgar, trehalose test and growth at 42°C were sequence ID using 1-2 genes, as well as all moulds (2 genes). S testing was performed against 7 antifungals (anidulafungin [ANF], caspofungin [CSF], micafungin [MCF], fluconazole [FLC], itraconazole, posaconazole [PSC], voriconazole [VRC]) using CLSI methods. R rates to all agents were determined using the new CLSI CBP and ECV criteria, as appropriate. Sequencing of fks hot spots was performed for EC non-WT strains. Results: Isolates included 3,107 Candida (20 species), 145 Aspergillus (11 species), 84 C. neoformans (CN), 37 other moulds (17 species), and 39 other yeasts (7 species). Among Candida, R to ANF, CSF, and MCF was low (0.0-1.7%). C. albicans (CA) and C. glabrata (CG) that were R to ANF, CSF, or MCF were shown to have fks mutations. R to FLC was low among isolates of CA (0.4%), C. tropicalis (CT; 1.3%) and C. parapsilosis (CP; 3.0%); 8.8% of CG were FLC-R. Among EC-R CG isolates from 2011, 38% were FLC-R. VRC was active against all Candida spp. except CG (10.5% non-WT) whereas PSC showed decreased activity against CA (7.8% non-WT) and C. krusei (15.2% non-WT). All agents except for the ECs and PSC were active vs. CN and the TZs were active vs. other yeasts (MIC90, 2 µg/ml). The ECs and TZs were active vs. Aspergillus (MIC/MEC90 range, 0.015-2 µg/ml), but were not active vs. other moulds (MIC/MEC90 range, 4->16 µg/ml). Conclusions: Overall, EC and TZ R rates were low; however, FLC and co-R among CG strains warrants continued close surveillance.
Abstract Number: M-330
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a